|Peer-reviewed||Experimental study||Animals, cells|
Blocking a pair of sugar-transporting proteins may be a useful treatment approach for lung cancer, suggests a new study in mice and human cells published today in eLife.
Cancer cells use a lot of sugar to fuel their rapid growth and spread. This has led scientists to consider cutting off their sugar supply as a way to treat cancer. The current study suggests this could be an effective approach but it will be necessary to block multiple pathways at once to be effective.
Proteins called glucose transporters supply sugar to cells making them an appealing target for therapies intended to starve cancer cells. But scientists don’t know the best ways to do this, or if cancer cells would just switch to alternative fuel sources if they are denied sugar.
“Inhibiting sugar use in lung tumours could be an efficient treatment strategy, but whether glucose transporters should be targeted and which ones to target remains unclear,” says lead author Caroline Contat, a PhD student and Doctoral Assistant at the Swiss Institute for Experimental Cancer Research, EPFL, Lausanne, Switzerland.
To find out, Contat and her colleagues genetically engineered mice with lung cancer that were missing a glucose transport protein called Glut1 or an alternate sugar transporter called Glut3. The team found that tumours grew just as fast in the mice lacking Glut1 or Glut3 as they did in mice with both transporters.
However, when they genetically engineered mice with lung cancer that lack both Glut1 and Glut3, they found that the animals grew fewer tumours and survived longer. By using an imaging technology called positron emission tomography (PET) and sugar labelled with radioactive tags, the team confirmed that the tumours used less sugar. The tumour cells also grew more slowly.
Finally, they deleted Glut1 and Glut3 in four different human lung cancer cell lines grown in the laboratory, which caused these cells to grow more slowly. “These experiments suggest Glut1 and Glut3 together are needed to fuel the growth of lung cancer,” Contat says.
Using nanoscale imaging studies, the team also found that most of the sugar-derived biomass in mouse lung tumour cells accumulates in cellular compartments called lamellar bodies and that Glut1 is necessary for this fuel storage.
“While more studies of these tumour fuel storage compartments are needed, our results suggest a new approach to lung cancer treatment that focuses on starving tumour cells of energy,” says senior author Etienne Meylan, Assistant Professor at the Swiss Institute for Experimental Cancer Research, EPFL. “In particular, treatments that block Glut1 and Glut3 simultaneously will be necessary to help stop lung tumour growth.”
eLife is a non-profit organisation created by funders and led by researchers. Our mission is to accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours. We work across three major areas: publishing, technology and research culture. We aim to publish work of the highest standards and importance in all areas of biology and medicine, including Cancer Biology, while exploring creative new ways to improve how research is assessed and published. We also invest in open-source technology innovation to modernise the infrastructure for science publishing and improve online tools for sharing, using and interacting with new results. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, the Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.
To read the latest Cancer Biology research published in eLife, visit https://elifesciences.org/subjects/cancer-biology.